Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin.

摘要: Abstract Background Coronary allograft vasculopathy (CAV) is a progressive complication after cardiac transplantation and limits survival. Hyperlipidemia known risk factor for CAV, pravastatin effective in decreasing cholesterol levels adults transplantation. However, few data exist regarding lipid profiles statin use pediatric heart We evaluated the prevalence of hyperlipidemia transplant recipients assessed efficacy safety therapy. Methods performed retrospective chart review ≥1 year surgery 50 to assess incidence hyperlipidemia. Twenty these patients received hypercholesterolemia. Their primary immunosuppression therapy was cyclosporine/prednisone plus either azathioprine or mycophenolate mofetil. reviewed serial profiles, creatinine phosphokinase, liver enzymes. Results Overall, 36% (n = 50) had total (TC) concentrations > 200 mg/dl 52% low-density lipoprotein (LDL) >110 mg/dL beyond 1 Of 20 treated with pravastatin, TC (236 ± 51 vs 174 33 mg/dl) LDL (151 32 99 21 decreased significantly (p Conclusions Hypercholesterolemia prevalent recipients. Pravastatin levels, seems be safe, tolerated well. Further studies are necessary determine whether treatment beneficial CAV.